Not sure that's accurate with RAC formulation having been used in Israeli trials.
A better way of putting that statement is, has any other small cap biotech company had such a platform of pre-clinical and historical data to support the advancement and approval of a newly patented FIC BIC drug (RC220).
The risk is RC220 IV platform doesn't work as planned but the upside for the IV over central line delivery system counters that.
Like others of late, I still believe Bisantrene has a mark to make in the oncology space but my faith in RAC to maintain FIC BIC status needs reinvigorating. AGM will hopefully be live streamed this year, should be interesting.
General Comments / Chat, page-8939
-
- There are more pages in this discussion • 2,925 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.040(2.37%) |
Mkt cap ! $281.2M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $50.53K | 30.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 539 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 731 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |